Why four years is important for BioMarin, hemophilia patients
June 01, 2020 at 10:45 AM EDT
BioMarin's gene therapy for patients with severe hemophilia A faces a FDA decision date of Aug. 21.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|